Aimmune Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aimmune Therapeutics, Inc.
Nestlé Ponders Least Painful Exit From Peanut Allergy Misfire
Heralded as a potential blockbuster, Nestlé's acquisition of Palforzia has proved to be a very expensive mistake.
2021: A Record-Breaking Year For ‘Smart’ Pricing And Access Deals In England
NHS England and Improvement (NHSE&I) agreed 16 pricing and access deals with drug companies in 2021, ten of which can be considered ‘smart.’ The fact that these were achieved against a backdrop of COVID-19 is seen as impressive.
German HTA Negative On Benefits Of First Ever Peanut Allergy Treatment
The decision by IQWiG could have an impact on how Palforzia is priced if the findings are upheld.
DBV Pulls EU Peanut Allergy Patch Filing To Work On A Stronger Application
Following regulatory setbacks in the US and also now in the EU, DBV Technologies is to conduct a new pivotal trial of a modified version of its peanut allergy patch to support its efforts to win marketing approval.
- Other Names / Subsidiaries
- Allergen Research Corporation (ARC)
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.